OTCPK:OMRX

Stock Analysis Report

Executive Summary

Orthometrix, Inc. develops technologies, procedures, and devices to help increase musculoskeletal mobility, as well as non-invasive technologies to treat the pain associated with osteoarthritis, plantar fasciitis, and other musculoskeletal conditions that reduce mobility.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Orthometrix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OMRX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

OMRX

0.08%

US Medical Equipment

-2.0%

US Market


1 Year Return

n/a

OMRX

-7.1%

US Medical Equipment

-15.1%

US Market

Return vs Industry: Insufficient data to determine how OMRX performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how OMRX performed against the US Market.


Shareholder returns

OMRXIndustryMarket
7 Day0%0.08%-2.0%
30 Day-8.4%-13.7%-19.7%
90 Day66.5%-18.1%-23.2%
1 Yearn/a-6.3%-7.1%-13.4%-15.1%
3 Year-8.4%-8.4%42.4%38.5%10.9%3.7%
5 Year-88.0%-88.0%71.1%53.4%28.4%14.4%

Price Volatility Vs. Market

How volatile is Orthometrix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Orthometrix undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Orthometrix is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Orthometrix has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of OMRX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Orthometrix regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Orthometrix forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orthometrix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Orthometrix performed over the past 5 years?

13.1%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Orthometrix has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Orthometrix's financial position?


In this section we usually analyse Orthometrix's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Orthometrix has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of OMRX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Orthometrix's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Orthometrix's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OMRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OMRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OMRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OMRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OMRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

US$2k

CEO Compensation


CEO

Reynald Bonmati (71yo)

no data

Tenure

US$1,701

Compensation

Mr. Reynald G. Bonmati, M.Sc. Ch.E., MBA serves as a Founder, Chief Executive Officer, President and Treasurer, of Orthometrix, Inc. Mr. Bonmati has been the Chief Executive Officer and the Chairman of And ...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Orthometrix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Orthometrix, Inc.
  • Ticker: OMRX
  • Exchange: OTCPK
  • Founded: 1993
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$194.915k
  • Shares outstanding: 53.21m
  • Website: https://null

Location

  • Orthometrix, Inc.
  • 5621 Strand Boulevard
  • Suite 111
  • Naples
  • Florida
  • 34110
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OMRXOTCPK (Pink Sheets LLC)YesCommon StockUSUSDAug 1995

Biography

Orthometrix, Inc. develops technologies, procedures, and devices to help increase musculoskeletal mobility, as well as non-invasive technologies to treat the pain associated with osteoarthritis, plantar fasciitis, and other musculoskeletal conditions that reduce mobility. The company markets, sells, and services peripheral quantitative computed tomography bone and muscle measurement systems for research and clinical applications; patented motorized exercise systems for rehabilitation, physical therapy, and sports medicine based on patented vibration technology; human performance measurement systems for monitoring improvement in power and mobility; and extracorporeal shock wave therapy systems for non-invasive treatment of pain associated with plantar fasciitis. It also markets, sells, and services patented motorized exercise systems to professional teams, fitness centers, gyms, sports clubs, and wellness-conscious general public. The company offers bone and muscle diagnostic, bone and muscle research, rehabilitation/physical therapy, sports and fitness, and home products. It serves healthcare, veterinary, and sports and fitness markets in the United States and internationally. The company was formerly known as Norland Medical Systems, Inc. and changed its name to Orthometrix, Inc. in April 2002. Orthometrix, Inc. was founded in 1993 and is headquartered in Naples, Florida. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/04 02:30
End of Day Share Price2020/03/25 00:00
Earnings2008/09/30
Annual Earnings2007/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.